Patient-specific muscle models pave way for personalized neuromuscular therapies

Scientists have so far identified around 800 different neuromuscular diseases. These conditions are caused by problems in the way muscle cells, motor neurons and peripheral cells interact.

Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

December 7, 2023

Rising antimicrobial resistance in STIs: A call for global action

Review delves into the rising challenge of antimicrobial resistance in sexually transmitted infections, underscoring the need for innovative treatments and the critical role of global

March 22, 2024

People in precarious employment more likely to die early, study says

People without a secure job contract can reduce their risk of premature death by 20 percent if they gain permanent employment, a study from Karolinska

September 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.